Cargando…

Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials

Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. In Japan, the proportion of new patients requiring dialysis due to DKD has remained unchanged over the past five years. Early diagnosis and treatment are extremely important for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gohda, Tomohito, Murakoshi, Maki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696577/ https://www.ncbi.nlm.nih.gov/pubmed/36430228 http://dx.doi.org/10.3390/ijms232213749

Ejemplares similares

The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
por: Li, Zi, et al.
Publicado: (2020)

Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease
por: Murakoshi, Maki, et al.
Publicado: (2020)

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
por: Wheeler, David C, et al.
Publicado: (2020)

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
por: Marx, Nikolaus, et al.
Publicado: (2021)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice
por: Ichikawa, Saki, et al.
Publicado: (2020)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Circulating kidney injury molecule‐1 as a biomarker of renal parameters in diabetic kidney disease
por: Gohda, Tomohito, et al.
Publicado: (2019)

Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease
por: Koshida, Takeo, et al.
Publicado: (2023)

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2021)

DAPA-CKD: The Beginning of a New Era in Renal Protection
por: Cherney, David Z.I., et al.
Publicado: (2021)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia
por: Gohda, Tomohito, et al.
Publicado: (2021)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
por: McEwan, Phil, et al.
Publicado: (2022)

Progranulin and Its Receptor Predict Kidney Function Decline in Patients With Type 2 Diabetes
por: Murakoshi, Maki, et al.
Publicado: (2022)

Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
por: Mohebi, Reza, et al.
Publicado: (2023)

COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease
por: Román, Juan León, et al.
Publicado: (2021)

Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data
por: Willis, Michael, et al.
Publicado: (2020)

Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients
por: Gohda, Tomohito, et al.
Publicado: (2022)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Effect of Exercise on Kidney Function, Oxidative Stress, and Inflammation in Type 2 Diabetic KK-A(y) Mice
por: Ishikawa, Yuji, et al.
Publicado: (2012)

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
por: Afsar, Baris, et al.
Publicado: (2022)

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis
por: Zhou, Zien, et al.
Publicado: (2021)

Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial
por: Young, Tamara K., et al.
Publicado: (2022)

Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study)
por: Hayashi, Terumasa, et al.
Publicado: (2018)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs
por: Sakuma, Hiroko, et al.
Publicado: (2020)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Of credence and credibility: A year gone by
por: Jain, Sanjay N
Publicado: (2014)

Commentary: Religious credence is not factual belief
por: Talmont-Kaminski, Konrad
Publicado: (2016)

Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?
por: Ehsan, Paghunda, et al.
Publicado: (2022)

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
por: Li, Jing‐Wei, et al.
Publicado: (2022)

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease
por: Wakisaka, Masanori, et al.
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

Prevention of Chronic kidney disease (CKD) in children
por: Pecoraro, Carmine
Publicado: (2015)

Chronic kidney disease (CKD) in disadvantaged populations
por: Garcia-Garcia, Guillermo, et al.
Publicado: (2015)

Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials
por: Jamil, Sidra, et al.
Publicado: (2022)

Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
por: Olufade, Tope, et al.
Publicado: (2021)

Chronic Kidney Disease, Queensland (CKD.QLD) Registry: Management of CKD With Telenephrology
por: Venuthurupalli, Sree K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nbu8cb5ck30tucjs5blmfj76ei